Decision Resources, Inc., Oct 2005, Pages: 19
should move toward a win-win model, in which the strategic objectives of each company are aligned. Overview
Biotechnology Licensing Trends
The Biotechnology Growth Engine
A New Phase of Maturity
Decision Resources, Inc., Aug 2008, Pages: 40
that process to create a win-win for all parties involved?
Scope
- Overview of the biotechnology startup landscape: market overview, market performance, 2007- 2008 IPOs, status of startups’ lead compounds
Global Industry Analysts, Inc., April 2010, Pages: 752
and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc
MP Advisors, Jan 2011, Pages: 391
market place the report provides a detailed sector overview and then recommends the companies that will succeed and explains why.
Each company analysis includes a detailed drug pipeline analysis
Decision Resources, Inc., June 2010, Pages: 29
favourable results by embracing strategies that have enabled them to win on all three fronts. These companies are at the core of industry growth because of their unparalleled strategic decision making, product
GlobalData, Dec 2011, Pages: 39
description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment
Markets and Markets, July 2010, Pages: 129
. This report will also provide more than 35 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report provides 30 company profiles for dental implants
Global Markets Direct, March 2011, Pages: 77
data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects
GlobalData, Oct 2011, Pages: 26
Oryzon Genomics - Product Pipeline Analysis
Summary
Oryzon Genomics (Oryzon) is a privately held biotechnologycompany, specialized in new biomarkers and therapeutic targets in oncology
PharmaVision, March 2009, Pages: 147
. Biotechnology drug candidates account for around 32 percent of all pipeline research programs. In addition, biological drugs are administered in life-saving or end-stage applications, 74 percent more than
GlobalData, Oct 2011, Pages: 28
launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company
Global Markets Direct, Nov 2011, Pages: 102
LEO Pharma A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
LEO 80190
NEO101
PEP005
LEO Pharma A/S – Company Statement
LEO Pharma A/S – Locations
Global Markets Direct, Dec 2009, Pages: 194
, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in North America
Scope
Arrowhead Publishers, May 2010, Pages: 261
players involved in the market and what strategies are they using to enhance product performance?
- What pharmaceutical/biotechnology and diagnostic companies are seeking alliances in 2010?
- How can
Bizacumen Inc., Nov 2009, Pages: 435
10
Newer Vaccines in Pipeline to Cheer Up Pharma Companies 10
Threat of Pandemic Rejuvenates Vaccine Market 10
Influenza Vaccines on a Growing
GlobalData, May 2010, Pages: 73
on company financials and pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis
PharmaVision, Nov 2007, Pages: 78
delivery technologies likely to reach the market?
4. Which delivery technologies and agents are likely to win in the near-term and the long-term, and why?
5. Which companies are the winners in each
GlobalData, Sep 2011, Pages: 41
. It is developing antivirals for the treatment of chronic hepatitis C and antibacterials for the treatment of resistant bacterial infections. The company's product pipeline includes ACH-1625, a protease inhibitor
Decision Resources, Inc., March 2009, Pages: 49
to treat unmet need in many cancers but also to the high cost of immunotherapies and biologics in general. Competition is increasing as more companies move into this arena; also, biosimilars will soon enter
Markets and Markets, April 2010, Pages: 118
a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus
